4//SEC Filing
Yang Arvin 4
Accession 0001104659-21-145951
CIK 0001442836other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 5:00 PM ET
Size
9.6 KB
Accession
0001104659-21-145951
Insider Transaction Report
Form 4
Yang Arvin
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-11-30+18,500→ 18,500 total - Sale
Common Stock
2021-12-01$6.81/sh−5,527$37,639→ 12,973 total - Exercise/Conversion
Restricted Stock Units
2021-11-30−18,500→ 18,500 total→ Common Stock (18,500 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
- [F2]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.68 to $7.00, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]50% of the total number of RSUs vested on November 30, 2021, and the remainder of the total number of RSUs shall vest on November 30, 2022.
Documents
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001834321
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 5:00 PM ET
- Size
- 9.6 KB